Independent investigators at the annual meeting of ASCO reported full results from the NEO3-09 study, reaffirming earlier top-line results that showed Neoprobe’s (AMEX:NEOP) Lymphoseek met all primary and secondary endpoints and exhibited superior performance to vital blue dye in intraoperative lymphatic mapping (ILM) procedures.
NEO3-09 is intended to be the final Phase 3 study for initial U.S. registration of the lymphatic tissue tracing agent. ”
“The results presented today reinforce prior clinical evidence indicating that Lymphoseek provides an improved modality for surgical oncologists to identify and diagnose potentially cancerous lymph nodes in breast cancer and melanoma versus the only currently approved agent, vital blue dye,” Neoprobe senior VP Dr. Fred Cope said in a statement. “
“Interestingly, these data also showed the potential ability for Lymphoseek to provide additional benefit to some patients by identifying cancerous lymph nodes that were missed by vital blue dye, which results in more accurate disease staging and ultimately patient treatment,” he added.
